Market Access Implementation

Real-World Evidence Strategy

Our Real-World Evidence Strategy service helps pharmaceutical companies design and execute RWE studies that support market access, regulatory submissions, and commercial positioning. We identify optimal data sources, design study protocols, and develop evidence generation roadmaps.

Key Benefits

How our real-world evidence strategy service delivers value to your organization.

Study Design

RWE study protocol design including population definition, exposure/outcome measures, and statistical analysis plan.

Data Source Identification

Identification and evaluation of optimal RWE data sources including claims, EHRs, registries, and patient-reported data.

Evidence Generation Roadmap

Multi-year evidence generation plan aligned with regulatory milestones, payer engagements, and commercial needs.

Regulatory-Grade Evidence

RWE studies designed to meet FDA and EMA requirements for regulatory submissions and label expansions.

What You Get

Comprehensive deliverables that provide actionable intelligence for your team.

RWE study protocol with statistical analysis plan
Data source evaluation report with access requirements and costs
Evidence generation roadmap with study timeline and milestones
Regulatory strategy for RWE submission with FDA/EMA requirements
HEOR-RWE integration plan for payer engagements
Study execution plan with vendor recommendations

Our Process

A structured methodology that delivers results in four phases.

01

Evidence Gap Analysis

Identify evidence gaps that RWE can address for regulatory, payer, and commercial needs.

02

Study Design

Design RWE study protocols with appropriate populations, comparators, outcomes, and statistical methods.

03

Data Strategy

Identify and evaluate data sources, negotiate data access, and plan data integration.

04

Execution Plan

Develop execution plan with timelines, budgets, vendor selection, and quality control.

Frequently Asked Questions

What RWE data sources do you work with?

We work with claims databases (MarketScan, Optum, Medicare), EHR networks, patient registries, pharmacy data, and emerging data sources like wearable devices and digital biomarkers.

Can RWE support regulatory submissions?

Yes, we design RWE studies that meet FDA Real-World Evidence Framework requirements and EMA requirements for regulatory submissions including label expansions and post-approval studies.

How do you ensure RWE study quality?

We follow ISPE GPP, ISPOR GPRWE, and FDA RWE Framework guidelines. All studies include protocol registration, bias mitigation, sensitivity analysis, and transparent reporting.

Ready to Get Started?

Connect with our team to discuss how our real-world evidence strategy service can support your goals.

Schedule a Consultation